← FDA Drug Approvals (Drugs@FDA)
DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA LIMITED · Approved 2025-06-12
Drug application
- FDA Application #
ANDA210811- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE
- Generic name
- Abacavir || Dolutegravir || Lamivudine
- Active ingredients
- ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
- Dosage form
- TABLET
- Route
- —
- Marketing status
- None (Tentative Approval)
- Sponsor
- CIPLA LIMITED
- First approval
- 2025-06-12
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown